Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
The changes of plasma amyloid beta (Abeta42) protein, homocysteine and medial temporal lobe atrophy (MTA) were studied by the transition from cognitive health to mild cognitive impairment (MCI) and to Alzheimer's disease (AD) in a prospective cohort of individuals aged 75 years. MTA but not plasma Abeta42 measured at baseline predicted which persons remained cognitively healthy (CH) and who developed AD 2.5 years later. The increase of plasma Abeta42 over time significantly distinguished between persons who remained CH on the one hand and MCI converters and AD converters out of cognitive health on the other (CH-to-MCI and CH-to-AD converters). Although both groups showed similar increase of Abeta42 levels, CH-to-AD converters had a higher increase of homocysteine compared to CH-to-MCI converters or to persons remaining CH. In comparison to all cognitive subgroups, the AD converters from MCI at baseline showed the smallest increase of Abeta42 levels and rather no increase of homocysteine. In logistic regression analysis, the increase of plasma Abeta42 but not change of MTA significantly predicted the conversion from CH to MCI, and changes of MTA and homocysteine but not of plasma Abeta42 predicted the conversion from CH to AD. The increase of plasma Abeta42 correctly allocated CH-to-MCI and CH-to-AD converters with low (63%) specificity (for both) and low (60%) sensitivity (54% for AD group). These results indicate that (1) plasma Abeta42 alone is not suitable as a biomarker for AD, (2) in the course of cognitive deterioration of the AD-type the increase of plasma Abeta42 seems to be an initial event, (3) similar to cerebrospinal fluid, changes of plasma Abeta42 may reflect the transition from cognitive health to AD, and (4) whether persons with MCI develop AD may depend on an accumulation of further toxic metabolites such as homocysteine.
Blasko
Imrich
I
Department of Psychiatry, Innsbruck Medical University, Austria.
Jellinger
Kurt
K
Kemmler
Georg
G
Krampla
Wolfgang
W
Jungwirth
Susanne
S
Wichart
Ildigo
I
Tragl
Karl Heinz
KH
Fischer
Peter
P
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000097:blood*; D001057:Apolipoproteins E / Q000235:genetics; D001284:Atrophy; D003072:Cognition Disorders / Q000097:blood* / Q000473:pathology*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005492:Folic Acid / Q000097:blood; D006711:Homocystine / Q000378:metabolism*; D006801:Humans; D016015:Logistic Models; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D009483:Neuropsychological Tests / Q000706:statistics & numerical data; D010446:Peptide Fragments / Q000097:blood*; D011237:Predictive Value of Tests; D011594:Psychometrics / Q000379:methods; D012189:Retrospective Studies; D013702:Temporal Lobe / Q000473:pathology*; D014805:Vitamin B 12 / Q000097:blood
D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D006711:Homocystine; D005492:Folic Acid; D014805:Vitamin B 12